Compare IVVD & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVVD | XYF |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | China |
| Employees | N/A | 643 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.9M | 193.4M |
| IPO Year | 2021 | 2018 |
| Metric | IVVD | XYF |
|---|---|---|
| Price | $0.53 | $4.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 46.3K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | ★ 11.34% |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | N/A |
| Revenue Next Year | $41.42 | N/A |
| P/E Ratio | ★ N/A | $0.90 |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $3.30 |
| 52 Week High | $3.07 | $16.40 |
| Indicator | IVVD | XYF |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 59.54 |
| Support Level | N/A | $4.86 |
| Resistance Level | $1.01 | $5.12 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 7.85 | 79.23 |
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.